AEZS

|

Aeterna Zentaris Inc

NASDAQ

USD
|%

Current Price

Change

(%)

P/E Ratio

Dividend Yield

Market Cap

17.51M

Volume

Open

Previous Close

52-Week High

USD 7.54

52-Week Low

USD 3.96

About Aeterna Zentaris Inc
Aeterna Zentaris Inc logo

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-on...

Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc.
Employees:
Headquarters:Toronto, Canada

Track AEZS and More with ZuneMoney

Get real-time updates, portfolio tracking, and dividend forecasts.

Dividend History
Dividend Payments
Declared DateRecord DatePayment DateAmountFrequency
Similar Companies
Frequently Asked Questions

Track AEZS and More with ZuneMoney

Get real-time updates, portfolio tracking, and dividend forecasts.